DDrare: Database of Drug Development for Rare Diseases

Gemcabene (DrugBank: Gemcabene)

2 diseases

ID	Disease name (Link within this page)	Number of trials
79	Homozygous familial hypercholesterolemia	1
265	Lipodystrophy	1

79. Homozygous familial hypercholesterolemia [ 128 clinical trials, 105 drugs, (DrugBank: 29 drugs), 8 drug target genes, 15 drug target pathways]

Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 128 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02722408 (ClinicalTrials.gov)	June 2016	12/3/2016	Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)	A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)	Hypercholesteremia	Drug: Gemcabene	NeuroBo Pharmaceuticals Inc.	NULL	Completed	17 Years	N/A	All	8	Phase 2	United States;Canada;Israel

265. Lipodystrophy [ 109 clinical trials, 164 drugs, (DrugBank: 59 drugs), 26 drug target genes, 94 drug target pathways]

Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 109 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03508687 (ClinicalTrials.gov)	March 13, 2018	3/4/2018	Study of Gemcabene in Adults With FPLD	An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD)	Familial Partial Lipodystrophy;Hypertriglyceridemia;Fatty Liver;NASH - Nonalcoholic Steatohepatitis	Drug: 300mg Gemcabene;Drug: 600mg Gemcabene	Elif Oral	NULL	Completed	18 Years	N/A	All	5	Phase 1;Phase 2	United States